Amyris, Inc. (NASDAQ:AMRS) Stock Rating Upgraded by Zacks Investment Research

Amyris, Inc. (NASDAQ:AMRS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, August 8th.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

Several other brokerages have also issued reports on AMRS. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Amyris in a report on Tuesday, May 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $25.70.

Amyris (AMRS) traded up 19.31% during mid-day trading on Tuesday, hitting $2.41. 764,244 shares of the stock were exchanged. The firm’s market cap is $90.63 million. The company has a 50 day moving average price of $3.37 and a 200 day moving average price of $5.63. Amyris has a 52-week low of $1.86 and a 52-week high of $18.15.

Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The firm had revenue of $25.68 million during the quarter, compared to analyst estimates of $23.68 million. Amyris’s revenue was up 167.5% compared to the same quarter last year. During the same period last year, the company posted ($0.06) EPS. On average, analysts anticipate that Amyris will post ($3.98) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Amyris, Inc. (NASDAQ:AMRS) Stock Rating Upgraded by Zacks Investment Research” was published by BNB Daily and is the property of of BNB Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at

A hedge fund recently raised its stake in Amyris stock. Carl Domino Inc increased its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned approximately 0.07% of Amyris worth $107,000 as of its most recent SEC filing.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply